Current Trends in Pharmacy Benefit Designs: A Threat to Disease Management in Chronic Complex Diseases

Abstract

With a focus on those patients who are candidates for treatment with biologic agents, we review the impact that current pharmacy benefit trends have on patients with chronic complex diseases and how they affect opportunities for disease management in this unique patient population. Dramatic increases in health care costs have led to a variety of strategies to manage cost. Many of these strategies either limit access to care or increase the patient's responsibility for choosing and paying for care, especially for medications. These strategies have a disproportionate impact on patients with chronic complex diseases, particularly those who require the use of biologic medications. A fundamental prerequisite of disease management has been coverage of disease-modifying therapies. If current pharmacy benefit trends continue, unintended consequences will likely occur including lost opportunities for disease management. Current pharmacy benefit trends could adversely impact disease management, particularly for patients requiring the use of biologic agents. Health plans should consider innovative benefit designs that reflect an appropriate level of cost sharing across all key stake-holders, ensuring appropriate access to needed therapies. Additional research is needed to clarify the value of newer approaches to therapies or benefit design changes.

C Terminus of Hsc70-interacting Protein Promotes Smooth Muscle Cell Proliferation and Survival through Ubiquitin-mediated Degradation of FoxO1

“…and lipids in the intima (1,2). Although the pathogenic mechanisms of atherosclerosis and restenosis are complex, the balance between proliferation and apoptosis of vascular SMCs seems to be a major factor in the progression of these diseases (1,2).…”

“…Although the pathogenic mechanisms of atherosclerosis and restenosis are complex, the balance between proliferation and apoptosis of vascular SMCs seems to be a major factor in the progression of these diseases (1,2). Various growth factors and cytokines are known to be involved in these processes (3)(4)(5)(6).…”